Bifogade filer
PDF
Kurs
-2,16%
Likviditet
1,95 MSEK
Kalender
| Est. tid* | ||
| 2026-02-06 | 08:30 | Bokslutskommuniké 2025 |
| 2025-10-24 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-04-10 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-04 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2025-04-03 | - | Årsstämma |
| 2025-02-05 | - | Bokslutskommuniké 2024 |
| 2024-10-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | Extra Bolagsstämma 2024 |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-10 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2024-04-09 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2023-05-02 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-05 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2022-04-04 | - | Årsstämma |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2021-05-10 | - | Årsstämma |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2020-04-02 | - | Årsstämma |
| 2020-03-10 | - | Extra Bolagsstämma 2020 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | Extra Bolagsstämma 2019 |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-09 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2019-04-08 | - | Årsstämma |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-20 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-10 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2018-04-09 | - | Årsstämma |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2017-05-22 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2017-02-20 | - | Extra Bolagsstämma 2017 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-19 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2016-05-24 | - | Årsstämma |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2015-05-06 | - | Årsstämma |
| 2015-05-06 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2014-06-03 | - | Årsstämma |
| 2014-05-09 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-21 | - | Bokslutskommuniké 2013 |
| 2014-02-12 | - | Extra Bolagsstämma 2014 |
| 2013-11-06 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-22 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-03 | - | X-dag ordinarie utdelning EPIS B 0.00 SEK |
| 2013-05-03 | - | Kvartalsrapport 2013-Q1 |
| 2013-05-02 | - | Årsstämma |
| 2013-04-03 | - | Extra Bolagsstämma 2013 |
| 2013-02-21 | - | Bokslutskommuniké 2012 |
| 2012-11-21 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-22 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-04 | - | Årsstämma |
| 2012-05-04 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-21 | - | Bokslutskommuniké 2011 |
| 2011-11-21 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-22 | - | Kvartalsrapport 2011-Q2 |
| 2011-07-20 | - | Split EPIS B 6:1 |
| 2011-06-30 | - | Årsstämma |
| 2011-05-21 | - | Kvartalsrapport 2011-Q1 |
| 2011-05-13 | - | Extra Bolagsstämma 2011 |
| 2011-05-02 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-18 | - | Bokslutskommuniké 2010 |
| 2010-08-30 | - | Extra Bolagsstämma 2010 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems. We reiterate our fair value of SEK1.3-3.9.
Long-term follow-up from first 10 patients treated. Episurf Medical reported the long-term follow-up for the first 10 patients treated with the Episealer implant system. These patients have now been followed for at least 75 months, and the outcome is just as good as after the last follow-up at 24 months. The basic result is that the positive outcomes seen at the 24-month follow-up remain after 75 months. We believe the lead investigator is set to publish the findings in a journal during the autumn.
Strong 24-month data maintaining efficacy at 75 months. As a reminder, the trial was conducted in 10 Swedish patients at three different clinics between December 2012 and November 2014. At the 24-month follow-up, the authors saw an improvement in all the scales used to assess the procedures. In particular, there was a statistically significant improvement in the VAS scale (p≤0.001), Tegner (p=0.034), KOOS subscale ADL (p=0.0048), sports and recreation (p=0.034), and quality of life (p=0.037). There were no revisions or implant migrations at 24 months. We have not yet had all the details (due to come in connection with publication of the findings), but believe the statement that all the positive findings seen at 24 months remain at 75 months indicates we should expect results at least as good when this trial is published.
These patients lack treatment options. As these patients are too old for biological treatments and too young for full knee replacements (median age at surgery: 42.5 years), there are no real options for this group. However, in order to be included in reimbursement systems and treatment algorithms at different clinics, long-term follow-up of the outcomes is usually very important. Hence we see this announcement as very positive for the ongoing market introduction of the implant system. We reiterate our fair value of SEK1.3-3.9.
Click here to view full report (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_162177.pdf&Sid=1-7XT0MIJ)
Best regards
__________________________________________________
Patrik Ling | DNB Markets | Equity Research | Senior Analyst Healthcare
DNB Bank ASA
Regeringsgatan 59 | Stockholm | Sweden